Alternative temozolomide dosing regimens and novel combinations for the treatment of advanced metastatic melanoma
Over the past 30 years, there has been no significant improvement in treatment outcomes for patients with advanced stage IV metastatic melanoma, and prognosis remains poor. Melanoma is known to be responsive to immunomodulatory agents, to be a highly vascular tumor, and to be fairly resistant to sta...
Main Authors: | Wen-Jen Hwu, Ana E. Ayala, Ingrid M. Hernandez |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2011-12-01
|
Series: | Oncology Reviews |
Subjects: | |
Online Access: | http://www.oncologyreviews.org/index.php/or/article/view/125 |
Similar Items
-
Quantitative Analysis of the <i>MGMT</i> Methylation Status of Glioblastomas in Light of the 2021 WHO Classification
by: Levin Häni, et al.
Published: (2022-06-01) -
Exploring the Mechanism of Adjuvant Treatment of Glioblastoma Using Temozolomide and Metformin
by: Shao-Wei Feng, et al.
Published: (2022-07-01) -
Rare Stochastic Expression of O6-Methylguanine- DNA Methyltransferase (MGMT) in MGMT-Negative Melanoma Cells Determines Immediate Emergence of Drug-Resistant Populations upon Treatment with Temozolomide In Vitro and In Vivo
by: Thomas C. Chen, et al.
Published: (2018-09-01) -
Prognostic genetic markers in malignant gliomas
by: Ralf Ketter, et al.
Published: (2010-12-01) -
Mechanism of in vitro sensitization of temozolomide to MGMT+ glioma cell line by FM19G11
by: FANG Huang-yi, YOU Chao-guo, PANG Chen, ZHANG Zhong-ding, ZHANG Zhe, KUANG Tong-shuai, SHENG Han-song
Published: (2021-04-01)